Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse

M. Perretti, Csaba Szabo, C. Thiemermann

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

1. The effect of systemic treatment of mice with murine recombinant interleukin-4 (IL-4) or interleukin-10 (IL-10) on neutrophil infiltration into a specific tissue site and nitric oxide (NO) production from peritoneal macrophages was investigated. 2. Intravenously (i.v.) administered IL-4 (0.01-10 μg per mouse, approximately 0.3-300 μg kg-1 i.v.) and IL-10 (0.01-1 μg per mouse, approximately 0.3-30 μg kg-1 i.v.) dose-dependently inhibited neutrophil accumulation into a 6-day-old murine air-pouch induced by local application of interleukin-1β (IL-1β, 5 ng), with approximate ED50s of 0.35 and 0.90 μg, respectively. Neither IL-4 (1 μg, 30 μg kg-1 i.v.) nor IL-10 (1 μg, 30 μg kg-1 i.v.) prevented leucocyte accumulation in the mouse air-pouches when interleukin-8 (IL-8, 1 μg) was used as chemoattractant. Similarly, neither cytokine had any effect on the in vitro up-regulation of CD11b antigen on the surface of murine circulating neutrophils. 3. Treatment of mice with lipopolysaccharide (LPS, 0.3 mg kg-1 i.p.) caused an increase in the formation of NO (measured as nitrite accumulation) in the supernatant of peritoneal macrophages ex vivo. Pretreatment of mice with IL-4 (0.01-1 μg i.v., 20 min before LPS), but not with IL-10 (1 μg i.v., 20 min before LPS), caused a dose-dependent reduction in this LPS-stimulated formation of nitrite by peritoneal macrophages ex vivo. 4. Activation of murine macrophages with LPS (1 μg ml-1 for 24 h) in vitro caused a significant increase in nitrite release in the supernatant of these cells. Pretreatment of either J774.2 or peritoneal macrophages with IL-4 (0.1-1 μg ml-1, 20 min before LPS), but not with IL-10 (1 μg ml-1, 20 min before LPS) caused a concentration-related attenuation of this LPS-stimulated nitrite formation. 5. Thus, both IL-4 and IL-10 inhibit the migration of leucocytes (stimulated by IL-1β) in vivo; IL-4 (but not IL-10) inhibits the induction of NO synthase caused by LPS in murine macrophages in vitro and ex vivo.

Original languageEnglish (US)
Pages (from-to)2251-2257
Number of pages7
JournalBritish Journal of Pharmacology
Volume116
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Interleukin-1
Interleukin-4
Interleukin-10
Nitric Oxide
Leukocytes
Peritoneal Macrophages
Nitrites
Interleukin-8
CD11b Antigens
Neutrophils
Air
Macrophage Activation
Neutrophil Infiltration
Chemotactic Factors
Interleukin-5
Nitric Oxide Synthase
Lipopolysaccharides
Up-Regulation
Macrophages
Cytokines

Keywords

  • CD11b
  • Inflammation
  • Interleukin-1
  • Interleukin-8
  • Neutrophils
  • Nitric oxide synthase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse. / Perretti, M.; Szabo, Csaba; Thiemermann, C.

In: British Journal of Pharmacology, Vol. 116, No. 4, 1995, p. 2251-2257.

Research output: Contribution to journalArticle

@article{72d60a2728c9469bb7f018ccdd915eb8,
title = "Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse",
abstract = "1. The effect of systemic treatment of mice with murine recombinant interleukin-4 (IL-4) or interleukin-10 (IL-10) on neutrophil infiltration into a specific tissue site and nitric oxide (NO) production from peritoneal macrophages was investigated. 2. Intravenously (i.v.) administered IL-4 (0.01-10 μg per mouse, approximately 0.3-300 μg kg-1 i.v.) and IL-10 (0.01-1 μg per mouse, approximately 0.3-30 μg kg-1 i.v.) dose-dependently inhibited neutrophil accumulation into a 6-day-old murine air-pouch induced by local application of interleukin-1β (IL-1β, 5 ng), with approximate ED50s of 0.35 and 0.90 μg, respectively. Neither IL-4 (1 μg, 30 μg kg-1 i.v.) nor IL-10 (1 μg, 30 μg kg-1 i.v.) prevented leucocyte accumulation in the mouse air-pouches when interleukin-8 (IL-8, 1 μg) was used as chemoattractant. Similarly, neither cytokine had any effect on the in vitro up-regulation of CD11b antigen on the surface of murine circulating neutrophils. 3. Treatment of mice with lipopolysaccharide (LPS, 0.3 mg kg-1 i.p.) caused an increase in the formation of NO (measured as nitrite accumulation) in the supernatant of peritoneal macrophages ex vivo. Pretreatment of mice with IL-4 (0.01-1 μg i.v., 20 min before LPS), but not with IL-10 (1 μg i.v., 20 min before LPS), caused a dose-dependent reduction in this LPS-stimulated formation of nitrite by peritoneal macrophages ex vivo. 4. Activation of murine macrophages with LPS (1 μg ml-1 for 24 h) in vitro caused a significant increase in nitrite release in the supernatant of these cells. Pretreatment of either J774.2 or peritoneal macrophages with IL-4 (0.1-1 μg ml-1, 20 min before LPS), but not with IL-10 (1 μg ml-1, 20 min before LPS) caused a concentration-related attenuation of this LPS-stimulated nitrite formation. 5. Thus, both IL-4 and IL-10 inhibit the migration of leucocytes (stimulated by IL-1β) in vivo; IL-4 (but not IL-10) inhibits the induction of NO synthase caused by LPS in murine macrophages in vitro and ex vivo.",
keywords = "CD11b, Inflammation, Interleukin-1, Interleukin-8, Neutrophils, Nitric oxide synthase",
author = "M. Perretti and Csaba Szabo and C. Thiemermann",
year = "1995",
language = "English (US)",
volume = "116",
pages = "2251--2257",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse

AU - Perretti, M.

AU - Szabo, Csaba

AU - Thiemermann, C.

PY - 1995

Y1 - 1995

N2 - 1. The effect of systemic treatment of mice with murine recombinant interleukin-4 (IL-4) or interleukin-10 (IL-10) on neutrophil infiltration into a specific tissue site and nitric oxide (NO) production from peritoneal macrophages was investigated. 2. Intravenously (i.v.) administered IL-4 (0.01-10 μg per mouse, approximately 0.3-300 μg kg-1 i.v.) and IL-10 (0.01-1 μg per mouse, approximately 0.3-30 μg kg-1 i.v.) dose-dependently inhibited neutrophil accumulation into a 6-day-old murine air-pouch induced by local application of interleukin-1β (IL-1β, 5 ng), with approximate ED50s of 0.35 and 0.90 μg, respectively. Neither IL-4 (1 μg, 30 μg kg-1 i.v.) nor IL-10 (1 μg, 30 μg kg-1 i.v.) prevented leucocyte accumulation in the mouse air-pouches when interleukin-8 (IL-8, 1 μg) was used as chemoattractant. Similarly, neither cytokine had any effect on the in vitro up-regulation of CD11b antigen on the surface of murine circulating neutrophils. 3. Treatment of mice with lipopolysaccharide (LPS, 0.3 mg kg-1 i.p.) caused an increase in the formation of NO (measured as nitrite accumulation) in the supernatant of peritoneal macrophages ex vivo. Pretreatment of mice with IL-4 (0.01-1 μg i.v., 20 min before LPS), but not with IL-10 (1 μg i.v., 20 min before LPS), caused a dose-dependent reduction in this LPS-stimulated formation of nitrite by peritoneal macrophages ex vivo. 4. Activation of murine macrophages with LPS (1 μg ml-1 for 24 h) in vitro caused a significant increase in nitrite release in the supernatant of these cells. Pretreatment of either J774.2 or peritoneal macrophages with IL-4 (0.1-1 μg ml-1, 20 min before LPS), but not with IL-10 (1 μg ml-1, 20 min before LPS) caused a concentration-related attenuation of this LPS-stimulated nitrite formation. 5. Thus, both IL-4 and IL-10 inhibit the migration of leucocytes (stimulated by IL-1β) in vivo; IL-4 (but not IL-10) inhibits the induction of NO synthase caused by LPS in murine macrophages in vitro and ex vivo.

AB - 1. The effect of systemic treatment of mice with murine recombinant interleukin-4 (IL-4) or interleukin-10 (IL-10) on neutrophil infiltration into a specific tissue site and nitric oxide (NO) production from peritoneal macrophages was investigated. 2. Intravenously (i.v.) administered IL-4 (0.01-10 μg per mouse, approximately 0.3-300 μg kg-1 i.v.) and IL-10 (0.01-1 μg per mouse, approximately 0.3-30 μg kg-1 i.v.) dose-dependently inhibited neutrophil accumulation into a 6-day-old murine air-pouch induced by local application of interleukin-1β (IL-1β, 5 ng), with approximate ED50s of 0.35 and 0.90 μg, respectively. Neither IL-4 (1 μg, 30 μg kg-1 i.v.) nor IL-10 (1 μg, 30 μg kg-1 i.v.) prevented leucocyte accumulation in the mouse air-pouches when interleukin-8 (IL-8, 1 μg) was used as chemoattractant. Similarly, neither cytokine had any effect on the in vitro up-regulation of CD11b antigen on the surface of murine circulating neutrophils. 3. Treatment of mice with lipopolysaccharide (LPS, 0.3 mg kg-1 i.p.) caused an increase in the formation of NO (measured as nitrite accumulation) in the supernatant of peritoneal macrophages ex vivo. Pretreatment of mice with IL-4 (0.01-1 μg i.v., 20 min before LPS), but not with IL-10 (1 μg i.v., 20 min before LPS), caused a dose-dependent reduction in this LPS-stimulated formation of nitrite by peritoneal macrophages ex vivo. 4. Activation of murine macrophages with LPS (1 μg ml-1 for 24 h) in vitro caused a significant increase in nitrite release in the supernatant of these cells. Pretreatment of either J774.2 or peritoneal macrophages with IL-4 (0.1-1 μg ml-1, 20 min before LPS), but not with IL-10 (1 μg ml-1, 20 min before LPS) caused a concentration-related attenuation of this LPS-stimulated nitrite formation. 5. Thus, both IL-4 and IL-10 inhibit the migration of leucocytes (stimulated by IL-1β) in vivo; IL-4 (but not IL-10) inhibits the induction of NO synthase caused by LPS in murine macrophages in vitro and ex vivo.

KW - CD11b

KW - Inflammation

KW - Interleukin-1

KW - Interleukin-8

KW - Neutrophils

KW - Nitric oxide synthase

UR - http://www.scopus.com/inward/record.url?scp=0028820014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028820014&partnerID=8YFLogxK

M3 - Article

C2 - 8564256

AN - SCOPUS:0028820014

VL - 116

SP - 2251

EP - 2257

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -